Early funding for biotechs slumps further in 2025 after several rough years

Port Therapeutics, a nimble biotech with well-known academic and executive names, went to more than 100 investors last year to move beyond the seed stage. But Port’s assets were still too far away from the ...

Apr 16, 2025 - 15:03
 0
Early funding for biotechs slumps further in 2025 after several rough years
Port Therapeutics, a nimble biotech with well-known academic and executive names, went to more than 100 investors last year to move beyond the seed stage. But Port’s assets were still too far away from the ...